Rates of new indication for antithrombotic drugs in people with cognitive impairment: implications for anti‐amyloid monoclonal antibody treatment
In this national sample of people with MCI or dementia, over 1 year, 7-8% of people were newly diagnosed with a cardiovascular disease requiring antithrombotic therapy. The risk of developing a condition for which anticoagulants or thrombolytics are indicated should be incorporated into discussions about anti-amyloid treatment to enhance shared decision-making.
Authors
- D. Kim
- Daniel M. Witt (ORCID: https://orcid.org/0000-0002-3930-8358)
- Jacquelyn M. Lykken (ORCID: https://orcid.org/0000-0003-0872-0873)
- Anna L. Parks (ORCID: https://orcid.org/0000-0003-1377-5406)
- Margaret C. Fang (ORCID: https://orcid.org/0000-0003-3362-1543)
- Meghan L. Rieu‐Werden
- Mark A. Supiano (ORCID: https://orcid.org/0000-0002-5438-5087)
- Darae Ko
- Steven M. Greenberg
- Sachin J Shah
Institutions
- Boston Medical Center (US)
- University of California, San Francisco (US)
- University of Utah (US)
- Massachusetts General Hospital (US)
- Hebrew SeniorLife (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70860_103167
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00